Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats Stage III or Stage IV Hodgkin Lymphoma. Sold as Matulane. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 1 application for Procarbazine hydrochloride (sold as Matulane), first approved Jul 22, 1969, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Matulane
Part D
$2.1M
+11%
237
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Matulane
$1.2M for 292 prescriptions, +12% on 2024
How its trials ended
37 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 12 whose ending is known, 67% met their primary endpoint, 0% missed it and 33% stopped early.
Completed, result not reported1849%Completed, result not reportedCount18Share49%
Met its primary endpoint822%Met its primary endpointCount8Share22%
Stopped: other or unclear411%Stopped: other or unclearCount4Share11%
Status unknown411%Status unknownCount4Share11%
Ongoing38%OngoingCount3Share8%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA